120099-60-7

Basic information

• Product Name: (R)-3-METHOXYPYRROLIDINE
• Synonyms: (3R)-3-METHOXYPYRROLIDINE;(R)-3-METHOXYPYRROLIDINE;R-3MEHP;Pyrrolidine, 3-methoxy-, (3R)-
• CAS NO: 120099-60-7
• Molecular Formula: C₅H₁₁NO
• Molecular Weight: 101.15
• Mol File: 120099-60-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 123℃
• Flash Point: 35℃
• Appearance: /
• Density: 0.94
• Vapor Pressure: 13.6mmHg at 25°C
• Refractive Index: 1.445
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.49±0.10(Predicted)
• CAS DataBase Reference: (R)-3-METHOXYPYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-METHOXYPYRROLIDINE(120099-60-7)
• EPA Substance Registry System: (R)-3-METHOXYPYRROLIDINE(120099-60-7)

Safety Data

• Hazardous Substances Data: 120099-60-7(Hazardous Substances Data)

Usage

Uses

(R)-3-Methoxypyrrolidine is used in the synthesis of spiroindane based imides as selective MC4R agonists for treating obesity.

InChI:InChI=1/C5H11NO/c1-7-5-2-3-6-4-5/h5-6H,2-4H2,1H3/t5-/m1/s1

Upstream product

• 74-88-4 methyl iodide 
• 549532-08-3 3R-methoxypyrrolidine-1-carboxylic acid tert-butyl ester 
• 672293-26-4 1-benzyl-3-(R)-methoxy-pyrrolidine 

Downstream Products

• 1243675-28-6 C₃₈H₅₀ClF₂N₃O₃ 
• 1360551-08-1 2-[4-(3-{(R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl}-[1,2,4]oxadiazol-5-yl)pyrazol-1-yl]-((R)-3-methoxypyrrolidin-1-yl)ethanone 

Relevant articles and documents

4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME

An object of the present invention is to provide a compound or a salt thereof having anti-HBV activity, a pharmaceutical composition, an anti-hepatitis B virus agent, a production inhibitor of DNA of a hepatitis B virus, and a production or secretion inhibitor of a hepatitis B surface antigen. According to the present invention, provided are a compound represented by General Formula [1] or a salt thereof: (in the formula, R1 represents a benzothiazolyl group which may be substituted (in which a carbon atom constituting the 6-membered ring of the benzothiazolyl group of R1 is bonded to the nitrogen atom of the pyridone ring); R2 represents a C2-6 alkenyl group which may be substituted, or the like; and R3 represents a hydrogen atom or the like).

OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently -(C1-C7) alkyl(optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence -H, -halogen, or -CH3.

Indole-type derivatives as inhibitors of p38 kinase

The invention is directed to methods to inhibit p38-α kinase using compounds comprising a phenyl or thienyl coupled through a piperidine or piperazine nucleus to an indole residue wherein the indole residue mandatorily has a substituent on the ring nitrogen which is an amino or substituted amino group.